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To the Editor: 38 
 Bronchiolitis is the most common lower respiratory infection in infants, and the leading 39 
cause of infant hospitalizations in the U.S. (approximately 130,000 hospitalizations annually).1 40 
Prior research has linked vitamin D status to bronchiolitis pathobiology. Indeed, 25-41 
hydroxyvitamin D (25OHD) undergoes enzymatic conversions to its biologically-active form, 42 
1,25-dihydroxyvitamin D (1,25OH2D), in immune cells (e.g., macrophages, dendritic cells and T 43 
cells), and plays a pleiotropic regulatory role on both innate and adaptive immune systems.2 44 
 Epidemiological investigations have reported the associations of lower blood 25OHD 45 
levels at birth or early infancy with an increased risk and severity of acute respiratory infections 46 
(ARIs), including bronchiolitis.2 Similarly, a 2017 meta-analysis of individual participant data 47 
from 25 trials demonstrated that vitamin D supplementation is protective against ARIs in 48 
subjects with low baseline 25OHD concentrations.3 While these earlier reports have evaluated 49 
circulating 25OHD levels in relation to disease processes,2,3 it remains unclear how vitamin D 50 
interacts with the numerous downstream functional molecules that can influence clinical 51 
outcomes. Metabolomics, a high-throughput technology, addresses this knowledge gap through 52 
comprehensively characterizing small-molecule metabolites that are a function of the infant’s 53 
genetic make-up and environmental factors,4 such as vitamin D status.  54 
 In the current study, by testing the serum metabolome from a nested subset of a 55 
multicenter bronchiolitis cohort study, we investigated the relationships between serum 25OHD 56 
levels, metabolome, and disease severity. More specifically, we tested the hypothesis that 57 
25OHD-related serum metabolites are associated with the risk of positive pressure ventilation 58 
(PPV) use among infants with bronchiolitis.  59 
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 This is an analysis of the data from a multicenter prospective cohort study of infants with 60 
severe bronchiolitis (i.e., bronchiolitis requiring hospitalization). Details of the study design, 61 
setting, subjects, data measurement, and analysis may be found in the Online Supplement 62 
(Supplemental Methods). In brief, the 35th Multicenter Airway Research Collaboration 63 
(MARC-35) cohort study5 enrolled 1,016 infants (age <1 year) hospitalized with bronchiolitis at 64 
17 sites across 14 U.S. states (Table E1) during the 2011–2014 winter seasons. Bronchiolitis 65 
was defined using the American Academy of Pediatrics guidelines – acute respiratory illness 66 
with some combination of rhinitis, cough, tachypnea, wheezing, crackles, and retractions.6 We 67 
excluded patients who were transferred to a participating hospital >24 hours after the original 68 
hospital admission, those who were consented >24 hours after admission, or those with known 69 
heart-lung disease, immunodeficiency, immunosuppression, or gestational age <32 weeks. The 70 
institutional review board of each participating hospital approved the study. We obtained written 71 
informed consent from the infant’s parent or guardian. 72 
 In addition to the collection of phenotypic data via structured interview and chart review, 73 
blood specimens were collected within 24 hours of hospitalization using a standardized 74 
protocol.5 Serum total 25OHD levels were quantified by immunoassays; bioavailable and free 75 
25OHD levels were computed using previously-validated formulas. Serum metabolites 76 
(metabolome) were profiled using ultra-high performance liquid chromatography-tandem mass 77 
spectrometry by Metabolon (Durham, NC, USA). The details of the tests and quality control 78 
measures may be found in Supplemental Methods. The clinical outcome of interest was the use 79 
of PPV – defined as use of continuous positive airway pressure and/or intubation during 80 
hospitalization.5  81 
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For the present analysis, we selected 140 infants who had sufficient volume of serum 82 
specimens and performed serum metabolomic profiling. First, to derive a subset of serum 83 
metabolites associated with the circulating 25OHD (three components – total, bioavailable, and 84 
free) levels, we constructed sparse partial least squares (sPLS) regression models with cross-85 
validation and LASSO regularization that minimize potential overfitting. The sPLS method has 86 
advances that it handles correlated variables (e.g., metabolites) and that it can also 87 
simultaneously model multiple response variables (total, bioavailable, and free 25OHD levels in 88 
the current study). To determine the association between each of these selected serum 89 
metabolites and the risk of PPV use, we next constructed multivariable logistic regression and 90 
random-effects models adjusting for age, sex, history of premature birth, feeding status, weight 91 
at presentation, in-hospital corticosteroid use, detected virus, and potential patient clustering 92 
within the hospitals. P-values were adjusted for multiple testing with the Benjamini-Hochberg 93 
false discovery rate (FDR) method. All analyses were conducted in R version 3.4.  94 
 95 
 The analytic (n=140) and non-analytic (n=876) cohorts were not significantly different 96 
for most patient characteristics, including the serum 25OHD levels (P>0.05; Table E2), except 97 
the analytic cohort had a lower proportion of respiratory syncytial virus infection and higher 98 
proportion of rhinovirus infection (both P<0.05). Of 140 infants in the analytic cohort, the 99 
median age was 3 months (interquartile range [IQR] 1-6 months), 62% were male, and 39% were 100 
non-Hispanic white. The median level of serum total 25OHD was 24.8 ng/ml (IQR 15.9-32.8 101 
ng/ml). Its level was significantly correlated with that of bioavailable 25OHD (r=0.73; P<0.001) 102 
and free 25OHD (r=0.66; P<0.001; Figure E1). Most patient characteristics did not differ 103 
significantly by total 25OHD status (Table 1), while infants with lower total 25OH levels were 104 
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younger, less likely to have a previous breathing problem, and had a lower weight at presentation 105 
(all P<0.05). Additionally, these infants had a higher likelihood of PPV use and longer hospital 106 
length-of-stay (both P<0.05) than those with higher total 25OHD levels. 107 
 Metabolomics testing of serum specimens detected a total of 707 named metabolites from 108 
96 sub-pathways in 8 super-pathways. Based on the sPLS ordination, the overall metabolome 109 
profiles clustered by total 25OHD status (Figures 1 and E2). By computing their loading scores 110 
with the sPLS model, we identified a set of top 20 serum metabolites that were most strongly 111 
associated with the serum 25OHD (total, bioavailable, and free) levels (Figures 2 and E3). 112 
These metabolites were products of predominantly lipid metabolism (11 metabolites), followed 113 
by amino acid/peptide, nucleotide, and carbohydrate metabolism. In the multivariable logistic 114 
regression models adjusting for potential confounders and the random-effects models accounting 115 
for site-effects, 9 of these 20 metabolites were significantly associated with the risk of PPV use 116 
(all FDR<0.05). Specifically, among the metabolites that were correlated with lower 25OHD 117 
levels, 3 metabolites – fibrinopeptide A, N1-methyladenosine, and sphingomyelin (d18:1/18:1, 118 
d18:2/18:0) – were associated with a significantly higher risk of PPV use (all FDR<0.05; Figure 119 
2). By contrast, among the metabolites that were correlated with higher 25OHD levels, 6 120 
metabolites – 1-(1-enyl-stearoyl)-2-oleoyl-glycerophosphorylethanolamine (GPE), 1-(1-enyl-121 
stearoyl)-2-linoleoyl-GPE, isoursodeoxycholate, 1-linoleoyl-glycerophosphate (GPA), glycerate, 122 
and glycylvaline – were associated with a significantly lower risk of PPV use (all FDR<0.05). 123 
The discrimination ability of the 20 selected metabolites on the risk of PPV use was high, with 124 
an area-under-the receiver operating characteristic curve of 0.92 (Figure E4). 125 
 126 
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 Based on the data from a prospective multicenter cohort of infants hospitalized for 127 
bronchiolitis, serum 25OHD levels were associated with differences in the serum metabolome 128 
profile – a metabolomic signature. Specifically, from the 707 named metabolites detected, we 129 
identified a set of 20 metabolites (predominantly lipids) that were associated with circulating 130 
25OHD (total, bioavailable, and free) levels. Among these, metabolites correlated with lower 131 
25OHD (e.g., sphingolipids) were associated with a significantly higher risk of PPV use. In 132 
contrast, metabolites correlated with higher 25OHD (e.g., plasmalogen pathway metabolites 133 
[GPE and GPA]) were associated with a significantly lower risk of PPV use. This is the first 134 
investigation that has examined the interrelationships between circulating 25OHD, metabolome, 135 
and clinical outcomes among infants with bronchiolitis. 136 
 Consistent with our observations, earlier reports of several disease conditions, including 137 
wheezing in young children, have found that the circulating total 25OHD concentrations were 138 
associated with specific blood and urine metabolomic profiles, particularly phospholipids.7,8 For 139 
instance, a recent nested case-control study of 84 children with recurrent wheeze (or asthma) and 140 
161 controls reported that, at age 3 years, the sphingolipid and glycerophospholipid (including 141 
GPE) metabolism pathways are associated with both serum 25OHD levels and clinical 142 
outcomes.7 The literature has also demonstrated that 1,25OH2D influences the metabolism of 143 
sphingolipids by regulating multiple components (e.g., the expression of sphingosine 1-144 
phosphate [S1P] phosphatase, S1P receptors, sphingomyelinase).9 Sphingolipids are not only 145 
building blocks of the cell membrane bilayer but also serve as signaling molecules with 146 
important roles in immune response and the pathobiology of inflammatory diseases (e.g., asthma, 147 
autoimmune diseases).9 Emerging evidence has also shown that an elevated level of 148 
sphingolipids in the upper airway is associated with higher severity in infants with bronchiolitis.5 149 
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 The current study also demonstrated that glycerophospholipids, particularly plasmalogen 150 
pathway metabolites (e.g., GPE and GPA), were associated with both higher circulating 25OHD 151 
levels and lower risk of PPV use. Consistent with this finding, a cohort study of 392 Finnish 152 
adults demonstrated the relationships between serum 25OHD levels and these lipids in the 153 
plasmalogen pathway.8 Plasmalogen is not only a major structural component of cell membrane 154 
and pulmonary surfactant, but also plays biological roles (e.g., generation of inflammatory 155 
mediators and protection against oxidation of surfactant lipids).10 The literature has also 156 
demonstrated that levels of plasmalogen are insufficient in premature infants with 157 
bronchopulmonary dysplasia and smokers with COPD.10 Our study corroborates these earlier 158 
reports, and extends them by demonstrating the interrelations between circulating 25OHD, 159 
metabolome, and disease severity in infants with bronchiolitis. 160 
 161 
 We acknowledge several potential limitations to the study. First, 25OHD and metabolites 162 
were measured early in the hospital course of critical illness at a single time-point and from a 163 
single bio-fluid (i.e., serum). Second, free and bioavailable 25OHD levels were not directly 164 
measured but computed using previously-validated formulas. Additionally, between-assay 165 
variability of total 25OHD measurement is possible because of the lack of standardization. Third, 166 
the current study did not have comparative metabolic information from a “healthy control” group 167 
of 25OHD-sufficient infants. Nonetheless, the study aim was not to evaluate the associations 168 
between 25OHD, metabolome, and the development of bronchiolitis, but to examine their 169 
contributions to acute severity among infants hospitalized for bronchiolitis. Fourth, we were 170 
unable to fully account for reverse causation and potential confounding, such as differences in 171 
intensive care resources. Yet, we statistically accounted for potential clustering of patients at the 172 
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hospital-level. Fifth, while we performed cross-validations and LASSO regularization to limit 173 
potential over-fitting, validation in a separate population is required to confirm our inferences. 174 
The findings are, however, consistent with recent publications on related topics.7,8 Finally, while 175 
the study population consisted of a racially/ethnically- and geographically-diverse sample, all 176 
were hospitalized for bronchiolitis and, as such, the findings may not be generalizable to children 177 
with mild-to-moderate bronchiolitis. Still, our inference remain directly relevant to 130,000 178 
hospitalized US children each year.1  179 
 180 
 In sum, based on the multicenter data of 140 infants hospitalized for bronchiolitis, we 181 
found that serum 25OHD levels were associated with a set of serum metabolites – a metabolomic 182 
signature. Among these, the metabolites correlated with lower 25OHD levels (e.g., 183 
sphingomyelin) were associated with a significantly higher risk of PPV use while those 184 
correlated with higher 25OHD levels (e.g., plasmalogen pathway metabolites) were associated 185 
with a lower risk. Although causality remains to be elucidated, prior research and our 186 
observations collectively suggest that circulating 25OHD, through affecting metabolites 187 
associated with inflammatory processes, may influence bronchiolitis severity. Our findings 188 
advance research into the complex interrelations between the environmental factors (e.g., vitamin 189 
D), host immunity, and the pathobiology of bronchiolitis in infants.  190 
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FIGURE LEGENDS 225 
Figure 1. Sparse partial least squares analysis score plot of serum metabolome according to 226 
total 25-hydroxyvitamin D levels 227 
Each dot represents the global serum metabolomic profile of a single infant, by plotting the 228 
component scores in the smaller subspace spanned by latent variables of sparse partial least 229 
squares (sPLS) model. The scatter plot indicates the similarities and dissimilarities in the global 230 
metabolome profile between infants, grouped by serum total 25OHD status (defined by the 231 
median values). The eclipses are 95% confidence intervals. The arrows start from the centroid of 232 
each group and end for each patient belonging to each group. 233 
 234 
Figure 2. Correlations between serum 25-hydroxyvitamin D (25OHD) and selected serum 235 
metabolites, and their associations with the risk of positive pressure ventilation use among 236 
infants hospitalized with bronchiolitis 237 
The heatmap (left) visualizes the correlations between the serum 25OHD (total, bioavailable, and 238 
free) levels and 20 selected metabolites that were examined using hierarchical clustering with an 239 
average linkage algorithm. The table (right) shows the adjusted associations between each of 240 
selected serum metabolites with the risk of PPV use. Bold results are statistically significant with 241 
FDR of <0.05. OR are calculated per each incremental increase in scaled level. 242 
Abbreviations: 25OHD, 25-hydroxyvitamin D; CI, confidence interval; FDR, false discovery 243 
rate; GPA, glycerophosphate; GPC, glycerophosphocholine; GPE, 244 
glycerophosphorylethanolamine; OR, odds ratio; sPLS, partial least squares. 245 
* Logistic regression models adjusting for patients’ age, sex, history of premature birth, feeding 246 
status, weight at presentation, corticosteroid use, and detected virus. 247 
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† Random-effects models adjusting for the covariates above and accounting for potential patient 248 
clustering within the hospitals. 249 
